Portable Fluorescence Immunoassay For Clinical Labs 2026

The Point-of-Care Challenge Facing Clinical Laboratories

Clinical laboratories around the world continue to rely heavily on traditional fluorescence immunoassay (FIA) testing performed on laboratory-bound instruments. While this approach has long been the standard for quantitative diagnostics, it carries structural limitations that are becoming harder to ignore. Traditional FIA testing is constrained by instruments that cannot leave the lab, requires relatively large sample volumes, and often results in long turnaround times and high operational costs. These constraints limit access to timely diagnostics precisely at the moment clinicians need them most—at the point of care.

For clinical laboratory professionals evaluating portable fluorescence immunoassay options, the core question is not whether portability matters, but whether a portable system can deliver laboratory-quality quantitative results without compromising accuracy, sample handling, or regulatory compliance. This is the exact gap that VivaChek Biotech (Hangzhou) Co., Ltd., operating under its VivaDiag diagnostic product brand, has focused its technology platform on addressing.

What Portable Fluorescence Immunoassay Technology Solves

Fluorescence immunoassay testing works by combining fluorescence immunochromatography with photoelectric detection to quantitatively measure biomarkers in human samples. VivaChek’s technology platform applies this principle across a fluorescence immunoassay (FIA) platform supporting quantitative determination for inflammatory, cardiac, diabetes, tumor marker, hormone, and other parameter categories.

The company’s proprietary R&D includes a fluorescence immunochromatography technology platform, a photoelectric detection based immunofluorescence detection device, and an ID Card coding system used for test parameter calibration. Together, these form the technical foundation that allows a handheld analyzer to replace certain laboratory-bound workflows without sacrificing quantitative precision.

The VIM300H: A Case Study in Portable Design

The VivaDiag Portable FIA Analyzer VIM300H illustrates how this platform translates into a usable clinical tool. The analyzer weighs 370 g, measures 146 x 77.6 x 55.5 mm, and runs for up to 10 hours on a removable and rechargeable lithium battery—specifications that support continuous operation across clinical shifts and mobile workflows without frequent recharging.

Beyond portability, the VIM300H is built around a 3.97-inch color touch screen, supports USB, Wi-Fi, and optional Bluetooth connectivity, and stores up to 10,000 results in memory. Its test menu spans 39 venous-blood parameters and more than 20 capillary-blood-ready parameters, covering sample types that include whole blood, serum, plasma, urine, hair, and other sample types. The ID Card coding system calibrates each test kit parameter at the point of use, a design choice intended to streamline operation and reduce training burden for laboratory professionals.

Operation temperature for the VIM300H is specified at 5–40°C, with storage temperature rated from -10–55°C, and the device includes unit conversion functionality. These operating parameters are relevant considerations for laboratories evaluating equipment for use outside controlled environments, including primary healthcare settings, emergency and pre-hospital care, and niche markets such as corporate health clinics, retail pharmacy testing services, and research or field operations.

How the VIM300H Compares to Prior VivaChek Models

VivaChek’s product history includes two earlier analyzer models that illustrate the company’s design trajectory. The VIM3000 is a 1.8 kg analyzer with a 7-inch color touch screen, a built-in thermal printer, and 10,000-result memory, with Ethernet port RJ-45 connectivity suited to laboratory and fixed-location settings requiring wired network integration. The VIM220H is a lighter, 165 g device with a 1.54-inch LCD display, a rechargeable lithium battery, and 999-result memory, built for scenarios where minimal size and weight take priority over display size or connectivity breadth.

Positioned between these two predecessors in design intent, the VIM300H combines a larger, more interactive touch screen than the VIM220H with a lighter, more mobile form factor than the VIM3000, while extending memory capacity to 10,000 results and adding Wi-Fi and optional Bluetooth connectivity. This progression reflects an iterative approach to balancing portability, display usability, and data connectivity for point-of-care and pre-hospital environments.

Quantitative Testing at the Point of Care: The PSA Test Kit Example

A portable analyzer is only as useful as the test kits available for it. The VivaDiag Prostate Specific Antigen (PSA) Test Kit (FIA) demonstrates how VivaChek pairs hardware with reagents to address a specific clinical need. Prostate cancer is the second most common cancer in men globally, with about 1.47 million new cases and about 400,000 deaths worldwide in 2022, according to the figures referenced in the company’s materials. Early prostate cancer often presents with few or no symptoms, which underscores the value of accessible screening and assessment tools, particularly as aging populations increase overall disease burden.

The PSA Test Kit quantitatively determines prostate specific antigen in human whole blood (obtained by fingerstick or venipuncture), serum, or plasma, delivering results in 15 minutes. It requires only a 20 μL sample volume, which enables fingerstick whole blood testing and reduces the barriers associated with venipuncture-only workflows. Its measuring range spans 0.1–100 ng/mL for serum and plasma, and 0.37–100 ng/mL for whole blood—a broader whole blood range than the 2–100 ng/mL range cited for compared competitor assays, enabling detection at lower PSA concentrations. The kit’s added mixed solution volume of 75 μL matches the lowest figure among the competitors referenced in the company’s comparative data.

Precision data reported for the kit shows intermediate precision coefficients of variation of 4.97% at low concentration, 4.05% at medium concentration, and 4.69% at high concentration, with an operation temperature range of 18–25°C and a cut-off reference range of 4 ng/mL. Each kit contains 25 test devices along with corresponding buffer tubes, safety lancets, alcohol prep pads, pipettes, and one ID Card, configured for use by clinical laboratory professionals as an aid in the management and monitoring of prostate cancer or other prostate disorders.

Regulatory Standing and Market Readiness

For laboratories operating in or exporting to European markets, regulatory status is a primary evaluation criterion. VivaChek’s PSA Test Kit and related system hold IVDR-certified status for professional use, supported by an EU Quality Management System Certificate under Regulation (EU) 2017/746 on In Vitro Diagnostic Devices, Annex IX Chapter I and III, and CE Marking with Notified Body Identification Number 0344, issued by DEKRA. These credentials are specific to professional-use in vitro diagnostic applications; the system is intended for use by clinical laboratory professionals and is not intended for self-testing or near-patient testing.

VivaChek, headquartered in Hangzhou, Zhejiang, China, has identified Germany, France, Italy, Spain, and the UK as priority markets within its broader European and global business coverage. As of the company’s most recent production update, 32 VIM300H sample units were made ready for distribution before the Mid-Autumn Festival, with approximately 78 finished units available for distribution by late October and trial production scheduled to conclude in December.

What This Means for Clinical Laboratory Decision-Makers

For clinical laboratories and point-of-care testing programs evaluating portable fluorescence immunoassay systems, the relevant decision factors are consistent: sample volume requirements, turnaround time, parameter breadth, battery life and portability, data connectivity, and regulatory certification for the target market. VivaChek’s VivaDiag platform—anchored by the VIM300H analyzer and test kits such as the PSA Test Kit (FIA)—addresses each of these factors with documented, specific technical parameters rather than general claims, offering laboratories a basis for direct, fact-based evaluation against their own testing requirements.

https://www.vivachek.com/
VivaChek Biotech (Hangzhou) Co., Ltd.